Analysis of Solvency Ratios
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Gilead Sciences Inc., solvency ratios
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Gilead Sciences Inc.’s financial leverage ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Gilead Sciences Inc.’s interest coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Gilead Sciences Inc.’s fixed charge coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Debt to Equity
Gilead Sciences Inc., debt to equity calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Total Gilead stockholders’ equity | 18,202 | 22,525 | 21,387 | 20,442 | 18,887 | |
| Solvency Ratio | ||||||
| Debt to equity1 | 1.73 | 1.09 | 1.28 | 1.64 | 1.39 | |
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| Abbott Laboratories | 0.57 | 0.58 | 0.64 | 0.90 | 1.07 | |
| AbbVie Inc. | 6.58 | — | — | 7.33 | 7.95 | |
| Amgen Inc. | 3.51 | 3.09 | 2.71 | 1.40 | 1.16 | |
| Bristol-Myers Squibb Co. | 1.34 | 0.91 | 0.52 | 0.68 | 0.41 | |
| Eli Lilly & Co. | 2.94 | 5.88 | 1.30 | 1.18 | 0.74 | |
| Illumina Inc. | 0.25 | 0.25 | 0.53 | 0.49 | 0.58 | |
| Johnson & Johnson | 0.56 | 0.47 | 0.51 | 0.57 | 0.39 | |
| Merck & Co. Inc. | 1.26 | 1.02 | 0.94 | 0.71 | 0.62 | |
| Pfizer Inc. | 0.63 | 0.83 | 0.66 | 0.61 | 0.71 | |
| Regeneron Pharmaceuticals Inc. | 0.24 | 0.06 | 0.08 | 0.11 | 0.11 | |
| Vertex Pharmaceuticals Inc. | 0.07 | 0.09 | 0.13 | 0.29 | 0.71 | |
| Zoetis Inc. | 1.91 | 2.38 | 2.95 | 2.80 | 3.00 | |
| Debt to Equity, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 1.12 | 1.00 | 0.94 | 0.84 | |
| Debt to Equity, Industry | ||||||
| Health Care | — | 0.91 | 0.83 | 0.84 | 0.79 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to equity = Total debt ÷ Total Gilead stockholders’ equity
= 31,402 ÷ 18,202 = 1.73
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Debt to Equity (including Operating Lease Liability)
Gilead Sciences Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Operating lease liabilities, current (classified in Other accrued liabilities) | 107 | 99 | — | — | — | |
| Operating lease liabilities, noncurrent (classified in Other long-term obligations) | 608 | 626 | — | — | — | |
| Total debt (including operating lease liability) | 32,117 | 25,318 | 27,322 | 33,542 | 26,346 | |
| Total Gilead stockholders’ equity | 18,202 | 22,525 | 21,387 | 20,442 | 18,887 | |
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | 1.76 | 1.12 | 1.28 | 1.64 | 1.39 | |
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.61 | 0.61 | 0.64 | 0.90 | 1.07 | |
| AbbVie Inc. | 6.66 | — | — | 7.33 | 7.95 | |
| Amgen Inc. | 3.55 | 3.15 | 2.71 | 1.40 | 1.16 | |
| Bristol-Myers Squibb Co. | 1.37 | 0.92 | 0.52 | 0.68 | 0.41 | |
| Eli Lilly & Co. | 3.06 | 6.11 | 1.30 | 1.18 | 0.74 | |
| Illumina Inc. | 0.41 | 0.41 | 0.53 | 0.49 | 0.58 | |
| Johnson & Johnson | 0.57 | 0.48 | 0.51 | 0.57 | 0.39 | |
| Merck & Co. Inc. | 1.32 | 1.06 | 0.94 | 0.71 | 0.62 | |
| Pfizer Inc. | 0.65 | 0.85 | 0.66 | 0.61 | 0.71 | |
| Regeneron Pharmaceuticals Inc. | 0.25 | 0.07 | 0.08 | 0.11 | 0.11 | |
| Vertex Pharmaceuticals Inc. | 0.11 | 0.11 | 0.13 | 0.29 | 0.71 | |
| Zoetis Inc. | 1.96 | 2.45 | 2.95 | 2.80 | 3.00 | |
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 1.15 | 1.00 | 0.94 | 0.84 | |
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | — | 0.94 | 0.83 | 0.84 | 0.79 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Gilead stockholders’ equity
= 32,117 ÷ 18,202 = 1.76
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Gilead Sciences Inc.’s debt to equity ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Debt to Capital
Gilead Sciences Inc., debt to capital calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Total Gilead stockholders’ equity | 18,202 | 22,525 | 21,387 | 20,442 | 18,887 | |
| Total capital | 49,604 | 47,118 | 48,709 | 53,984 | 45,233 | |
| Solvency Ratio | ||||||
| Debt to capital1 | 0.63 | 0.52 | 0.56 | 0.62 | 0.58 | |
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| Abbott Laboratories | 0.36 | 0.37 | 0.39 | 0.47 | 0.52 | |
| AbbVie Inc. | 0.87 | 1.14 | 1.27 | 0.88 | 0.89 | |
| Amgen Inc. | 0.78 | 0.76 | 0.73 | 0.58 | 0.54 | |
| Bristol-Myers Squibb Co. | 0.57 | 0.48 | 0.34 | 0.40 | 0.29 | |
| Eli Lilly & Co. | 0.75 | 0.85 | 0.57 | 0.54 | 0.42 | |
| Illumina Inc. | 0.20 | 0.20 | 0.35 | 0.33 | 0.37 | |
| Johnson & Johnson | 0.36 | 0.32 | 0.34 | 0.37 | 0.28 | |
| Merck & Co. Inc. | 0.56 | 0.50 | 0.48 | 0.42 | 0.38 | |
| Pfizer Inc. | 0.39 | 0.45 | 0.40 | 0.38 | 0.41 | |
| Regeneron Pharmaceuticals Inc. | 0.20 | 0.06 | 0.07 | 0.10 | 0.10 | |
| Vertex Pharmaceuticals Inc. | 0.06 | 0.09 | 0.12 | 0.22 | 0.42 | |
| Zoetis Inc. | 0.66 | 0.70 | 0.75 | 0.74 | 0.75 | |
| Debt to Capital, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 0.53 | 0.50 | 0.48 | 0.46 | |
| Debt to Capital, Industry | ||||||
| Health Care | — | 0.48 | 0.45 | 0.46 | 0.44 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 31,402 ÷ 49,604 = 0.63
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Debt to Capital (including Operating Lease Liability)
Gilead Sciences Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Operating lease liabilities, current (classified in Other accrued liabilities) | 107 | 99 | — | — | — | |
| Operating lease liabilities, noncurrent (classified in Other long-term obligations) | 608 | 626 | — | — | — | |
| Total debt (including operating lease liability) | 32,117 | 25,318 | 27,322 | 33,542 | 26,346 | |
| Total Gilead stockholders’ equity | 18,202 | 22,525 | 21,387 | 20,442 | 18,887 | |
| Total capital (including operating lease liability) | 50,319 | 47,843 | 48,709 | 53,984 | 45,233 | |
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | 0.64 | 0.53 | 0.56 | 0.62 | 0.58 | |
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.38 | 0.38 | 0.39 | 0.47 | 0.52 | |
| AbbVie Inc. | 0.87 | 1.14 | 1.27 | 0.88 | 0.89 | |
| Amgen Inc. | 0.78 | 0.76 | 0.73 | 0.58 | 0.54 | |
| Bristol-Myers Squibb Co. | 0.58 | 0.48 | 0.34 | 0.40 | 0.29 | |
| Eli Lilly & Co. | 0.75 | 0.86 | 0.57 | 0.54 | 0.42 | |
| Illumina Inc. | 0.29 | 0.29 | 0.35 | 0.33 | 0.37 | |
| Johnson & Johnson | 0.36 | 0.33 | 0.34 | 0.37 | 0.28 | |
| Merck & Co. Inc. | 0.57 | 0.51 | 0.48 | 0.42 | 0.38 | |
| Pfizer Inc. | 0.39 | 0.46 | 0.40 | 0.38 | 0.41 | |
| Regeneron Pharmaceuticals Inc. | 0.20 | 0.06 | 0.07 | 0.10 | 0.10 | |
| Vertex Pharmaceuticals Inc. | 0.10 | 0.10 | 0.12 | 0.22 | 0.42 | |
| Zoetis Inc. | 0.66 | 0.71 | 0.75 | 0.74 | 0.75 | |
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 0.54 | 0.50 | 0.48 | 0.46 | |
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | — | 0.48 | 0.45 | 0.46 | 0.44 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 32,117 ÷ 50,319 = 0.64
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Gilead Sciences Inc.’s debt to capital ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Debt to Assets
Gilead Sciences Inc., debt to assets calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Total assets | 68,407 | 61,627 | 63,675 | 70,283 | 56,977 | |
| Solvency Ratio | ||||||
| Debt to assets1 | 0.46 | 0.40 | 0.43 | 0.48 | 0.46 | |
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| Abbott Laboratories | 0.26 | 0.27 | 0.29 | 0.37 | 0.42 | |
| AbbVie Inc. | 0.57 | 0.75 | 0.68 | 0.53 | 0.56 | |
| Amgen Inc. | 0.52 | 0.50 | 0.51 | 0.44 | 0.45 | |
| Bristol-Myers Squibb Co. | 0.43 | 0.36 | 0.21 | 0.24 | 0.20 | |
| Eli Lilly & Co. | 0.36 | 0.39 | 0.29 | 0.30 | 0.27 | |
| Illumina Inc. | 0.16 | 0.16 | 0.29 | 0.25 | 0.30 | |
| Johnson & Johnson | 0.20 | 0.18 | 0.20 | 0.22 | 0.19 | |
| Merck & Co. Inc. | 0.35 | 0.31 | 0.30 | 0.28 | 0.26 | |
| Pfizer Inc. | 0.26 | 0.31 | 0.26 | 0.25 | 0.25 | |
| Regeneron Pharmaceuticals Inc. | 0.16 | 0.05 | 0.06 | 0.08 | 0.07 | |
| Vertex Pharmaceuticals Inc. | 0.05 | 0.07 | 0.09 | 0.16 | 0.28 | |
| Zoetis Inc. | 0.53 | 0.56 | 0.60 | 0.58 | 0.58 | |
| Debt to Assets, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 0.35 | 0.32 | 0.32 | 0.31 | |
| Debt to Assets, Industry | ||||||
| Health Care | — | 0.33 | 0.31 | 0.32 | 0.31 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 31,402 ÷ 68,407 = 0.46
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Debt to Assets (including Operating Lease Liability)
Gilead Sciences Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current portion of long-term debt and other obligations, net | 2,757 | 2,499 | 2,748 | 2,747 | — | |
| Long-term debt, net, excluding current portion | 28,645 | 22,094 | 24,574 | 30,795 | 26,346 | |
| Total debt | 31,402 | 24,593 | 27,322 | 33,542 | 26,346 | |
| Operating lease liabilities, current (classified in Other accrued liabilities) | 107 | 99 | — | — | — | |
| Operating lease liabilities, noncurrent (classified in Other long-term obligations) | 608 | 626 | — | — | — | |
| Total debt (including operating lease liability) | 32,117 | 25,318 | 27,322 | 33,542 | 26,346 | |
| Total assets | 68,407 | 61,627 | 63,675 | 70,283 | 56,977 | |
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | 0.47 | 0.41 | 0.43 | 0.48 | 0.46 | |
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| Abbott Laboratories | 0.27 | 0.28 | 0.29 | 0.37 | 0.42 | |
| AbbVie Inc. | 0.58 | 0.75 | 0.68 | 0.53 | 0.56 | |
| Amgen Inc. | 0.53 | 0.51 | 0.51 | 0.44 | 0.45 | |
| Bristol-Myers Squibb Co. | 0.44 | 0.37 | 0.21 | 0.24 | 0.20 | |
| Eli Lilly & Co. | 0.37 | 0.41 | 0.29 | 0.30 | 0.27 | |
| Illumina Inc. | 0.25 | 0.26 | 0.29 | 0.25 | 0.30 | |
| Johnson & Johnson | 0.21 | 0.18 | 0.20 | 0.22 | 0.19 | |
| Merck & Co. Inc. | 0.37 | 0.32 | 0.30 | 0.28 | 0.26 | |
| Pfizer Inc. | 0.27 | 0.32 | 0.26 | 0.25 | 0.25 | |
| Regeneron Pharmaceuticals Inc. | 0.16 | 0.05 | 0.06 | 0.08 | 0.07 | |
| Vertex Pharmaceuticals Inc. | 0.08 | 0.08 | 0.09 | 0.16 | 0.28 | |
| Zoetis Inc. | 0.54 | 0.58 | 0.60 | 0.58 | 0.58 | |
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 0.36 | 0.32 | 0.32 | 0.31 | |
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | — | 0.34 | 0.31 | 0.32 | 0.31 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 32,117 ÷ 68,407 = 0.47
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Gilead Sciences Inc.’s debt to assets ratio (including operating lease liability) improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Financial Leverage
Gilead Sciences Inc., financial leverage calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | 68,407 | 61,627 | 63,675 | 70,283 | 56,977 | |
| Total Gilead stockholders’ equity | 18,202 | 22,525 | 21,387 | 20,442 | 18,887 | |
| Solvency Ratio | ||||||
| Financial leverage1 | 3.76 | 2.74 | 2.98 | 3.44 | 3.02 | |
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| Abbott Laboratories | 2.21 | 2.18 | 2.20 | 2.47 | 2.56 | |
| AbbVie Inc. | 11.51 | — | — | 13.89 | 14.26 | |
| Amgen Inc. | 6.69 | 6.17 | 5.31 | 3.17 | 2.60 | |
| Bristol-Myers Squibb Co. | 3.13 | 2.52 | 2.49 | 2.86 | 2.08 | |
| Eli Lilly & Co. | 8.27 | 15.07 | 4.47 | 3.88 | 2.77 | |
| Illumina Inc. | 1.62 | 1.59 | 1.85 | 1.91 | 1.95 | |
| Johnson & Johnson | 2.76 | 2.65 | 2.56 | 2.61 | 2.01 | |
| Merck & Co. Inc. | 3.62 | 3.26 | 3.09 | 2.56 | 2.38 | |
| Pfizer Inc. | 2.44 | 2.65 | 2.51 | 2.41 | 2.88 | |
| Regeneron Pharmaceuticals Inc. | 1.56 | 1.34 | 1.34 | 1.43 | 1.57 | |
| Vertex Pharmaceuticals Inc. | 1.35 | 1.37 | 1.41 | 1.75 | 2.50 | |
| Zoetis Inc. | 3.61 | 4.26 | 4.93 | 4.85 | 5.14 | |
| Financial Leverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 3.18 | 3.08 | 2.89 | 2.67 | |
| Financial Leverage, Industry | ||||||
| Health Care | — | 2.77 | 2.68 | 2.66 | 2.54 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= 68,407 ÷ 18,202 = 3.76
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Gilead Sciences Inc.’s financial leverage ratio decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
Interest Coverage
Gilead Sciences Inc., interest coverage calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | 123 | 5,386 | 5,455 | 4,628 | 13,501 | |
| Add: Net income attributable to noncontrolling interest | (34) | (22) | 5 | 16 | (13) | |
| Add: Income tax expense | 1,580 | (204) | 2,339 | 8,885 | 3,609 | |
| Add: Interest expense | 984 | 995 | 1,077 | 1,118 | 964 | |
| Earnings before interest and tax (EBIT) | 2,653 | 6,155 | 8,876 | 14,647 | 18,061 | |
| Solvency Ratio | ||||||
| Interest coverage1 | 2.70 | 6.19 | 8.24 | 13.10 | 18.74 | |
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| Abbott Laboratories | 10.10 | 7.09 | 4.48 | 3.47 | 4.28 | |
| AbbVie Inc. | 2.38 | 5.72 | 4.86 | 7.72 | 8.53 | |
| Amgen Inc. | 7.44 | 8.09 | 7.86 | 8.36 | 8.27 | |
| Bristol-Myers Squibb Co. | -3.84 | 8.58 | 33.61 | 27.18 | 36.42 | |
| Eli Lilly & Co. | 21.11 | 14.15 | 14.95 | 10.77 | 19.22 | |
| Illumina Inc. | 18.47 | 22.50 | 16.68 | 29.19 | 17.91 | |
| Johnson & Johnson | 83.07 | 55.49 | 18.91 | 19.92 | 28.28 | |
| Merck & Co. Inc. | 11.58 | 13.84 | 12.27 | 9.65 | 7.72 | |
| Pfizer Inc. | 6.17 | 12.23 | 10.03 | 10.69 | 8.04 | |
| Regeneron Pharmaceuticals Inc. | 67.97 | 81.43 | 91.55 | 83.75 | 185.82 | |
| Vertex Pharmaceuticals Inc. | 54.60 | 24.84 | 9.28 | 0.77 | 0.17 | |
| Zoetis Inc. | 9.64 | 9.08 | 9.20 | 9.71 | 8.40 | |
| Interest Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 11.09 | 10.29 | 10.99 | 12.62 | |
| Interest Coverage, Industry | ||||||
| Health Care | — | 9.95 | 9.71 | 10.14 | 10.74 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Interest coverage = EBIT ÷ Interest expense
= 2,653 ÷ 984 = 2.70
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Gilead Sciences Inc.’s interest coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Fixed Charge Coverage
Gilead Sciences Inc., fixed charge coverage calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to Gilead | 123 | 5,386 | 5,455 | 4,628 | 13,501 | |
| Add: Net income attributable to noncontrolling interest | (34) | (22) | 5 | 16 | (13) | |
| Add: Income tax expense | 1,580 | (204) | 2,339 | 8,885 | 3,609 | |
| Add: Interest expense | 984 | 995 | 1,077 | 1,118 | 964 | |
| Earnings before interest and tax (EBIT) | 2,653 | 6,155 | 8,876 | 14,647 | 18,061 | |
| Add: Operating lease expense | 171 | 162 | 109 | 84 | 81 | |
| Earnings before fixed charges and tax | 2,824 | 6,317 | 8,985 | 14,731 | 18,142 | |
| Interest expense | 984 | 995 | 1,077 | 1,118 | 964 | |
| Operating lease expense | 171 | 162 | 109 | 84 | 81 | |
| Fixed charges | 1,155 | 1,157 | 1,186 | 1,202 | 1,045 | |
| Solvency Ratio | ||||||
| Fixed charge coverage1 | 2.45 | 5.46 | 7.58 | 12.26 | 17.36 | |
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| Abbott Laboratories | 6.68 | 5.14 | 4.48 | 3.47 | 4.28 | |
| AbbVie Inc. | 2.28 | 5.42 | 4.44 | 6.86 | 7.54 | |
| Amgen Inc. | 6.48 | 7.12 | 7.13 | 7.56 | 7.57 | |
| Bristol-Myers Squibb Co. | -3.08 | 7.10 | 20.07 | 17.24 | 19.96 | |
| Eli Lilly & Co. | 15.06 | 10.18 | 8.66 | 5.89 | 9.31 | |
| Illumina Inc. | 7.44 | 9.22 | 8.98 | 13.57 | 8.11 | |
| Johnson & Johnson | 33.93 | 28.72 | 14.46 | 14.53 | 19.75 | |
| Merck & Co. Inc. | 8.47 | 10.31 | 8.95 | 7.03 | 5.73 | |
| Pfizer Inc. | 4.98 | 9.88 | 8.34 | 8.76 | 6.64 | |
| Vertex Pharmaceuticals Inc. | 39.35 | 20.79 | 7.69 | 0.82 | 0.33 | |
| Zoetis Inc. | 8.21 | 7.85 | 7.73 | 8.55 | 7.43 | |
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals & Biotechnology | — | 9.00 | 8.63 | 9.13 | 10.29 | |
| Fixed Charge Coverage, Industry | ||||||
| Health Care | — | 7.68 | 7.66 | 7.99 | 8.46 | |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
1 2020 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= 2,824 ÷ 1,155 = 2.45
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Gilead Sciences Inc.’s fixed charge coverage ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |